文献速递间质性肺疾病

Pamrevlumab治疗特发性肺纤维化的2期随机双盲安慰剂对照试验(PRAISE)

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2019-09-28

这项2期随机双盲安慰剂对照试验在7国39中心纳入103例特发性肺纤维化患者,评估抗结缔组织生长因子单抗pamrevlumab的疗效与安全性。

要点

  • pamrevlumab显著减缓特发性肺纤维化患者FVC下降。
  • pamrevlumab组疾病进展比例低于安慰剂组。
  • pamrevlumab安全性与安慰剂相似,耐受性良好。

核心结论

  • pamrevlumab减缓特发性肺纤维化进展且耐受性良好,已进入3期开发。

研究设计与样本

  • 2期随机双盲安慰剂对照试验在7国39中心进行,纳入预测FVC≥55%的特发性肺纤维化患者103例,按1:1随机接受pamrevlumab 30 mg/kg或安慰剂每3周静脉输注,共48周16次输注。

主要发现

  • 治疗中出现严重不良事件:pamrevlumab组12例(24%),安慰剂组8例(15%)。
  • 死亡:pamrevlumab组3例(6%),安慰剂组6例(11%),均认为与治疗无关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Connective tissue growth factor (CTGF) is a secreted glycoprotein that has a central role in the process of fibrosis. This study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis. The aim was to establish whether pamrevlumab could slow, stop, or reverse progression of idiopathic pulmonary fibrosis. METHODS: The phase 2, randomised, double-blind, placebo-controlled PRAISE trial was done at 39 medical centres in seven countries (Australia, Bulgaria, Canada, India, New Zealand, South Africa, and the USA). Patients with idiopathic pulmonary fibrosis and percentage of predicted forced vital capacity (FVC) of 55% or greater were enrolled and randomly assigned (1:1) by use of interactive responsive technology to intravenous infusion of pamrevlumab 30 mg/kg or placebo every 3 weeks over 48 weeks (16 infusions). The primary efficacy outcome was change from baseline in percentage of predicted FVC at week 48. Disease progression (defined as a decline from baseline in percentage of predicted FVC of ≥10%, or death) at week 48 was a key secondary efficacy outcome. All patients in the pamrevlumab group received at least one dose of the study drug and were analysed for safety. Two patients in the placebo group were excluded from the intention-to-treat population for the efficacy analyses because of enrolment error. This trial is registered with ClinicalTrials.gov, NCT01890265. FINDINGS: Between Aug 17, 2013, and July 21, 2017, 103 patients were randomly assigned (50 to pamrevlumab and 53 to placebo). Pamrevlumab reduced the decline in percentage of predicted FVC by 60·3% at week 48 (mean change from baseline -2·9% with pamrevlumab vs -7·2% with placebo; between-group difference 4·3% [95% CI 0·4-8·3]; p=0·033). The proportion of patients with disease progression was lower in the pamrevlumab group than in the placebo group at week 48 (10·0% vs 31·4%; p=0·013). Pamrevlumab was well tolerated, with a safety profile similar to that of placebo. Treatment-emergent serious adverse events were observed in 12 (24%) patients in the pamrevlumab group and eight (15%) in the placebo group, with three patients on pamrevlumab and seven on placebo discontinuing treatment. Of the three (6%) deaths in the pamrevlumab group and six (11%) in the placebo group, none was considered treatment related. INTERPRETATION: Pamrevlumab attenuated progression of idiopathic pulmonary fibrosis and was well tolerated. Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis. FUNDING: FibroGen.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2019. PMID: 31575509. doi:10.1016/S2213-2600(19)30262-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。